Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
KAIROS PHARMA LTD (KAPA)
AMEXHealth CareBiotechnologySnapshot 2026-11-04
$0.45-7.22%
Close 2026-11-05 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for KAPA yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Improvement in EPS losses | A primary condition in KAIROS PHARMA LTD's published investment case. The stated target is EPS loss improves from -$0.37 in FY26 to less negative or stable in FY27. | Broken | EPS loss worsens beyond -$0.67 in FY27 | Diluted EPS: $-0.06 per share FY2026-Q2; GAAP. Published target: EPS loss improves from -$0.37 in FY26 to less negative or stable in FY27. Annual target cannot be compared with a quarterly or TTM observation. Aug 12, 2026-0.06 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 13, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative clinical-stage growth, not an established earnings compounder, because KAPA is loss-making and carries high risk. The thesis is in a watch state: management is stable, but recent financial performance trails its industry cohort and confidence in the evidence is low.
The snapshot provides no valuation measure or direct evidence of what the market expects, so whether KAPA is cheap or expensive versus peers cannot be assessed. The available evidence points to high uncertainty rather than a clear expectations gap.
Near-term results may remain difficult to judge because KAPA is loss-making and the snapshot flags an elevated risk of missing expectations. Over the multi-year view, ENV-105 has a clinical signal, while the CL-741 study and Bayer collaboration are still early and have no reported outcomes.
The thesis depends on whether ENV-105’s early clinical signal holds up as trials advance, and whether CL-741 and the Bayer collaboration produce measurable progress. Near term, a guidance cut or further job-market weakening would add pressure; continued strength among healthcare bellwethers would support the sector backdrop.
Over the next 1 to 3 years, KAPA’s long-term thesis rests on turning early clinical progress into stronger evidence, while financial and execution risks remain high. The evidence is limited and confidence is low. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Successful integration and advancement of the lung cancer asset acquisition | Kairos Pharma advances with its acquisition of a lung cancer asset, supporting growth in oncology. | Improving | Failure to complete acquisition or no clinical progress by end 2026 | Acquisition in progress (Term Sheet signed Mar 2026) vs Target: Completion by end 2026 Kairos signed a binding term sheet with Celyn Therapeutics on March 2, 2026, to acquire the lung cancer asset CL-273. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Start of revenue generation from pipeline assets | A supporting condition in KAIROS PHARMA LTD's published investment case. The stated target is Positive revenue reported by FY27. | Broken | No revenue reported by FY27 | Revenue: $0 FY2026-Q2; GAAP. Published target: Positive revenue reported by FY27. Annual target cannot be compared with a quarterly or TTM observation. Aug 12, 20260 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.51 → $-4.69 · observed estimates
Unavailable → Unavailable · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.51 | Unavailable | 1 / 0 |
| 2026-07-25 | $-0.51 | Unavailable | 1 / 0 |
| 2026-07-26 | $-0.51 | Unavailable | 1 / 0 |
| 2026-07-27 | $-0.51 | Unavailable | 1 / 0 |
| 2026-07-28 | $-0.67 | $0 | 1 / 2 |
| 2026-07-29 | $-0.67 | $0 | 1 / 2 |
| 2026-07-30 | $-0.67 | $0 | 1 / 2 |
| 2026-07-31 | $-0.67 | $0 | 1 / 2 |
| 2026-08-01 | $-0.51 | Unavailable | 1 / 0 |
| 2026-08-02 | $-0.67 | $0 | 1 / 2 |
| 2026-08-03 | $-0.67 | $0 | 1 / 2 |
| 2026-08-04 | $-0.67 | $0 | 1 / 2 |
| 2026-08-05 | $-0.51 | Unavailable | 1 / 0 |
| 2026-08-06 | $-0.51 | Unavailable | 1 / 0 |
| 2026-08-07 | $-0.51 | Unavailable | 1 / 0 |
| 2026-08-08 | $-0.67 | $0 | 1 / 2 |
| 2026-08-09 | $-0.51 | Unavailable | 1 / 0 |
| 2026-08-10 | $-0.51 | Unavailable | 1 / 0 |
| 2026-08-12 | $-0.67 | $0 | 1 / 2 |
| 2026-08-13 | $-0.51 | Unavailable | 1 / 0 |
| 2026-08-14 | $-0.51 | Unavailable | 1 / 0 |
| 2026-08-15 | $-0.51 | Unavailable | 1 / 0 |
| 2026-08-16 | $-0.51 | Unavailable | 1 / 0 |
| 2026-08-17 | $-0.51 | Unavailable | 1 / 0 |
| 2026-08-18 | $-0.51 | Unavailable | 1 / 0 |
| 2026-08-19 | $-0.51 | Unavailable | 1 / 0 |
| 2026-08-20 | $-0.51 | Unavailable | 1 / 0 |
| 2026-08-21 | $-0.51 | Unavailable | 1 / 0 |
| 2026-08-22 | $-0.51 | Unavailable | 1 / 0 |
| 2026-08-23 | $-0.51 | Unavailable | 1 / 0 |
| 2026-08-24 | $-0.51 | Unavailable | 1 / 0 |
| 2026-08-25 | $-0.51 | Unavailable | 1 / 0 |
| 2026-08-26 | $-0.51 | Unavailable | 1 / 0 |
| 2026-08-27 | $-0.51 | Unavailable | 1 / 0 |
| 2026-08-28 | $-0.51 | Unavailable | 1 / 0 |
| 2026-08-29 | $-0.51 | Unavailable | 1 / 0 |
| 2026-08-30 | $-0.51 | Unavailable | 1 / 0 |
| 2026-08-31 | $-0.51 | Unavailable | 1 / 0 |
| 2026-09-01 | $-0.51 | Unavailable | 1 / 0 |
| 2026-09-02 | $-3.54 | Unavailable | 1 / 0 |
| 2026-09-03 | $-3.54 | Unavailable | 1 / 0 |
| 2026-09-04 | $-3.54 | Unavailable | 1 / 0 |
| 2026-09-05 | $-3.54 | Unavailable | 1 / 0 |
| 2026-09-06 | $-3.54 | Unavailable | 1 / 0 |
| 2026-09-07 | $-3.54 | Unavailable | 1 / 0 |
| 2026-09-08 | $-3.54 | Unavailable | 1 / 0 |
| 2026-09-09 | $-3.54 | Unavailable | 1 / 0 |
| 2026-09-10 | $-3.54 | Unavailable | 1 / 0 |
| 2026-09-11 | $-3.54 | Unavailable | 1 / 0 |
| 2026-09-12 | $-3.54 | Unavailable | 1 / 0 |
| 2026-09-13 | $-3.54 | Unavailable | 1 / 0 |
| 2026-09-14 | $-3.54 | Unavailable | 1 / 0 |
| 2026-09-15 | $-3.54 | Unavailable | 1 / 0 |
| 2026-09-16 | $-3.54 | Unavailable | 1 / 0 |
| 2026-09-17 | $-3.54 | Unavailable | 1 / 0 |
| 2026-09-18 | $-3.54 | Unavailable | 1 / 0 |
| 2026-09-19 | $-3.54 | Unavailable | 1 / 0 |
| 2026-09-20 | $-3.54 | Unavailable | 1 / 0 |
| 2026-09-21 | $-3.54 | Unavailable | 1 / 0 |
| 2026-09-22 | $-3.54 | Unavailable | 1 / 0 |
| 2026-09-23 | $-3.54 | Unavailable | 1 / 0 |
| 2026-09-24 | $-3.54 | Unavailable | 1 / 0 |
| 2026-09-25 | $-3.54 | Unavailable | 1 / 0 |
| 2026-09-26 | $-3.54 | Unavailable | 1 / 0 |
| 2026-09-27 | $-3.54 | Unavailable | 1 / 0 |
| 2026-09-28 | $-3.54 | Unavailable | 1 / 0 |
| 2026-09-29 | $-3.54 | Unavailable | 1 / 0 |
| 2026-09-30 | $-3.54 | Unavailable | 1 / 0 |
| 2026-10-01 | $-3.54 | Unavailable | 1 / 0 |
| 2026-10-02 | $-3.54 | Unavailable | 1 / 0 |
| 2026-10-03 | $-3.54 | Unavailable | 1 / 0 |
| 2026-10-04 | $-3.54 | Unavailable | 1 / 0 |
| 2026-10-05 | $-3.54 | Unavailable | 1 / 0 |
| 2026-10-06 | $-3.54 | Unavailable | 1 / 0 |
| 2026-10-07 | $-3.54 | Unavailable | 1 / 0 |
| 2026-10-08 | $-3.54 | Unavailable | 1 / 0 |
| 2026-10-09 | $-3.54 | Unavailable | 1 / 0 |
| 2026-10-10 | $-3.54 | Unavailable | 1 / 0 |
| 2026-10-11 | $-3.54 | Unavailable | 1 / 0 |
| 2026-10-12 | $-3.54 | Unavailable | 1 / 0 |
| 2026-10-13 | $-3.54 | Unavailable | 1 / 0 |
| 2026-10-14 | $-3.54 | Unavailable | 1 / 0 |
| 2026-10-15 | $-3.54 | Unavailable | 1 / 0 |
| 2026-10-16 | $-3.54 | Unavailable | 1 / 0 |
| 2026-10-17 | $-3.54 | Unavailable | 1 / 0 |
| 2026-10-18 | $-3.54 | Unavailable | 1 / 0 |
| 2026-10-19 | $-3.54 | Unavailable | 1 / 0 |
| 2026-10-20 | $-3.54 | Unavailable | 1 / 0 |
| 2026-10-21 | $-3.54 | Unavailable | 1 / 0 |
| 2026-10-22 | $-3.54 | Unavailable | 1 / 0 |
| 2026-10-23 | $-3.54 | Unavailable | 1 / 0 |
| 2026-10-24 | $-3.54 | Unavailable | 1 / 0 |
| 2026-10-25 | $-3.54 | Unavailable | 1 / 0 |
| 2026-10-26 | $-3.54 | Unavailable | 1 / 0 |
| 2026-10-27 | $-3.54 | Unavailable | 1 / 0 |
| 2026-10-28 | $-3.54 | Unavailable | 1 / 0 |
| 2026-10-29 | $-3.54 | Unavailable | 1 / 0 |
| 2026-10-30 | $-3.54 | Unavailable | 1 / 0 |
| 2026-10-31 | $-4.69 | Unavailable | 1 / 0 |
| 2026-11-01 | $-4.69 | Unavailable | 1 / 0 |
| 2026-11-02 | $-4.69 | Unavailable | 1 / 0 |
| 2026-11-03 | $-4.69 | Unavailable | 1 / 0 |
| 2026-11-04 | $-4.69 | Unavailable | 1 / 0 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.